Background: Recently, it has been discovered, upstream of the interferon-λ3 protein (IFNL3) (also termed IL28B) on chromosome 19, a new transiently induced region that harbors a dinucleotide variant ss469415590 (TT or ΔG), which is in high linkage disequilibrium with rs12979860. ss469415590 (ΔG) is a frameshift variant that creates a novel gene, designated IFNL4, which is moderately similar to IFNL3. Importantly, ss469415590 may have a functional role in the innate immune response to HCV. Since there are no data about the impact of IFNL4 ss469415590 polymorphisms on treatment outcomes in HCV/HIV-1 coinfected patients, we decide to investigate the role of the ss469415590 SNP in a well characterized cohort of HCV/HIV-1 coinfected patients that were treated with pegIFN-α/RBV. Methodology: The prevalence of the ss469415590 TT/ΔG substitution, as well as the rs12979860 polymorphism, was analyzed in a cohort of 207 patients from our clinic with chronic HCV and HIV-1 coinfection and with a known response to treatment with pegIFN-α/RBV at 24 weeks post-treatment. ss469415590 and rs12979860 genotyping was performed using the ABI TaqMan allelic discrimination kit and the ABI7500HT Sequence Detection System. The association of ss469415590 and rs12979860 polymorphisms with response to treatment was performed by univariate and multivariate logistic regression as implemented in the SNPStats software. Results: ss469415590 and rs12979860 polymorphisms were in strong linkage disequilibrium (R2 = 0.95) and both had a minor allele frequency of 0.32. The ss469415590 minor allele frequency was identical to that found for Europeans in the HapMap samples (0.07 frequency in Asians, 0.32 frequency in Europeans and 0.73 frequency in Africans). We next correlated the ss469415590 and rs12979860 genotypes with the HCV pegIFN-α/RBV treatment response. Both polymorphisms were associated with response to treatment. However, ss469415590 had a more significant association with response to treatment (OR = 3.12, 95% CI 1.1.72-5.67, P = 0.0001) than rs12979860 (OR = 2.60, 95% CI 1.45-4.69, P = 0.0012). Remarkably, ss469415590 had also a stronger association in a multivariate model, after adjustment for age, sex, HCV RNA load and fibrosis stage (OR = 3.56, 95% Cl 1.80-7.03, P = 0.0002) than rs12979860 (OR = 2.99, 95% CI 1.53-5.84, P = 0.001). Conclusions: These results demonstrate that ss469415590 is a better marker of sustained viral response than rs12979860.